Bal Pharma share news, announcements and annual reports
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Bal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, May 2006 on NSE
Last close ₹84.61down ₹1.56 (1.81%)BSE ₹84.35
Share price at the NSE close on 29 Oct 2026. Previous close ₹86.17.
29 Oct: open ₹86.50, high ₹86.89, low ₹84.12
52-week range of traded prices to 29 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹135 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.69
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.64
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.42%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,181
Bal Pharma disputes and clarifications
27 filed, newest first.
Sep 2026
10 Sep · Legal
The exchange asked on 10 Sep 2026
Jul 2026
Jun 2026
22 Jun · Legal
Exchange has sought clarification from Bal Pharma Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies. The response of the Company is awaited.
Jun 2023
9 Jun · Legal
Exchange has sought clarification from Bal Pharma Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jul 2022
Jun 2022
29 Jun · Legal
Exchange has sought clarification from Bal Pharma Limited with respect to announcement dated 30-May-2022 informing about appointment of Mr. Kotian Chittananda Damodar as Additional Director.On the basis of aforesaid announcement, the Company is required to provide/clarify the following:Change in directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), Auditor and Compliance Officer: 1. Disclosure of relationships between directors (in case of appointment of a director) 2. Reason for change viz. appointment, resignation, removal, death or otherwise 3. Brief profile (in case of appointment) 4. Date of appointment/cessation (as applicable) and term of appointment 5. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority The response of the company is awaited.
Jul 2021
5 Jul · Legal
Exchange has sought clarification from Bal Pharma Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Apr 2021
27 Apr · Legal
The exchange asked on 26 Apr 2021
Oct 2020
13 Oct · Legal
The exchange asked on 12 Oct 2020
Aug 2020
6 Aug · Legal
Exchange has sought clarification from Bal Pharma Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange.2. Machine Readable Form / Legible copy of Financial Results not submitted.The response of the Company is awaited.
Nov 2019
25 Nov · Legal
Exchange has sought clarification from Bal Pharma Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Statement of Cash Flow not submitted The response of the Company is awaited.15 Nov · Legal
Exchange has sought clarification from Bal Pharma Limited with respect to announcement dated 15-Nov-2019, regarding Outcome of Board Meeting held on November 14, 2019. On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointmentThe response of the Company is awaited.
Sep 2019
Aug 2019
19 Aug · Legal
Exchange has sought clarification from Bal Pharma Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Dec 2018
14 Dec · Legal
Exchange has sought clarification from Bal Pharma Limited with respect to announcement dated 03-Dec-2018, regarding " Bal Pharma Limited has informed the Exchange regarding 'Commencement of commercial production.Disclosure as per Regulation 30 of SEBI(LODR) Regulations. With reference to the above, we would like to inform the exchange that after obtaining all the regulatory approvals, our bulk drugs manufacturing unit at Udaipur has commenced its commercial production of intermediates and Active Pharma Ingredients (API). The API products which of scheduled to be manufactured at this Unit were developed by our R&D facility at Bangalore and due to capacity constraints at our Bangalore facility they could not become commercially viable till now. This unit is expected to ease the capacity concerns of API's and intermediates and will cater to the North are Northeastern markets of the country and also overseas markets. To recapitulate, we have acquired 100% share holding and management control of Golden Drugs Pvt Ltd, Udaipur, Rajasthan, during March 2018, which is into manufacturing of API's and intermediates, Please take this intimation on record.'.". On basis of above the Company is required to clarify following: 1. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief). 2. Percentage of shareholding / control acquired and / or number of shares acquired; 3. Nature of consideration - whether cash consideration or share swap and details of the same; 4. Cost of acquisition or the price at which the shares are acquired; 5. Indicative time period for completion of the acquisition; 6. Brief details of any governmental or regulatory approvals required for the acquisition; 7. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); 8. Industry to which the entity being acquired belongs; 9. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; 10. Name of the target entity, details in brief such as size, turnover etc; The response of the Company is awaited.
Jun 2018
May 2018
30 May · Legal
Exchange has sought clarification from Bal Pharma Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted -2. Financial results not signed by authorized signatory/ies -3. Consolidated Reconciliation of profit and loss not submitted -4. Consolidated Reconciliation of Equity not submitted. The response of the Company is awaited.
Mar 2018
26 Mar · Legal
Exchange has sought clarification from Bal Pharma Limited with respect to announcement dated 23-Mar-2018, regarding 'Disclosure as per Regulation 30 of the SEBI (LODR) Regulations.'.". On basis of above the Company is required to clarify following: 1. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).2. Percentage of shareholding / control acquired and / or number of shares acquired;3. Nature of consideration - whether cash consideration or share swap and details of the same;4. Cost of acquisition or the price at which the shares are acquired;5. Indicative time period for completion of the acquisition;6. Brief details of any governmental or regulatory approvals required for the acquisition;7. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);8. Industry to which the entity being acquired belongs;9. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";10. Name of the target entity, details in brief such as size, turnover etc;The response of the Company is awaited.
Sep 2017
12 Sep · Legal
Exchange has sought clarification from Bal Pharma Limited with respect to announcement dated 12-Sep-2017, regarding " Outcome of Board Meeting held on September 11, 2017." On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.